ArticleBMC nephrology2025
Development and validation of a single-nephron estimated glomerular filtration rate model to predict disease progression in IgA nephropathy.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe highly variable clinical progression of IgA nephropathy (IgAN) makes it challenging to accurately predict the risk of disease deterioration in patients. Although elevated single-nephron estimated glomerular filtration rate (eGFR) is implicated in disease progression, its prognostic utility remains underexplored due to methodological limitations in nephron quantification. This study aims to fill this research gap by establishing single-nephron eGFR as a prognostic factor and developing a predictive nomogram for assessing kidney disease progression in IgAN patients.
methodsWe included 190 patients with biopsy-proven IgAN undergoing kidney biopsy and CT imaging. Single-nephron eGFR was calculated by dividing eGFR by nephron number, derived from cortical volume and glomerular density. A Cox model incorporating clinical, pathological, and single-nephron eGFR parameters was developed (training cohort: n = 133) and validated (validation cohort: n = 57). Kidney function decline was defined as an annual eGFR decrease ≥5 ml/min/1·73 m2, ≥40% eGFR reduction, or end-stage renal disease. Model performance was assessed using Harrell’s C-index, time-dependent AUC, and calibration curves.
resultsOf the 410 patients screened, 190 (46%) met the eligibility criteria. The cohort was 55% male patients, with a median age of 36 years (IQR, 30–47). The median follow-up duration was 37 months (IQR, 22–48). The nomogram included smoking history, eGFR, use of calcium channel blockers, and single-nephron eGFR. It demonstrated good discrimination (C-index 0.76 [0.69–0.82] in training; 0.75 [0.65–0.85] in validation) with good calibration. Low-risk patients had significantly longer survival compared to high-risk patients in both the development (P < 0.001) and validation (P = 0.04) cohorts. An interactive Shiny app was developed for clinical use (https://yangchenkay.shinyapps.io/IgAN/).
conclusionsThis study develops a clinically applicable prediction model for IgAN that underscores the prognostic value of single-nephron eGFR in renal outcome and enables effective risk stratification of kidney function decline in patients with IgAN. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.